Oxford Cancer (Oxford University Hospitals and University of Oxford)

Oxford Cancer unites the Oxford University Hospitals cancer and haematology services at the Churchill Hospital with the University of Oxford's Department of Oncology, the Oxford Institute for Radiation Oncology (descended from the Gray Laboratory's hypoxia research), the Ludwig Institute for Cancer Research Oxford branch and the Weatherall Institute of Molecular Medicine. The CRUK Oxford Centre and Oxford Centre for Early Cancer Detection focus on prevention, screening and liquid biopsy, while the Oxford Cancer and Haematology Centre runs early-phase and radiotherapy trials. Oxford science underpins companies such as Immunocore (from Avidex, whose tebentafusp became the first TCR bispecific approved for uveal melanoma) and Oxford Nanopore, and the ChAdOx vaccine platform is being tested for cancer vaccines. Patients access one of the UK's largest haematology and transplant programmes and a growing sarcoma and colorectal service.